Beranda › Karsinoma Sel Skuamosa Kepala dan Leher › Indiana
Uji klinis Karsinoma Sel Skuamosa Kepala dan Leher di Indiana
13 studi untuk Karsinoma Sel Skuamosa Kepala dan Leher mencari peserta di lokasi di Indiana.
Kota di Indiana
Teks studi resmi (Bahasa Inggris)
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
- IU Simon Cancer Center, Indianapolis
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 2 Okt 2026 · NCT06465069Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
- Exelixis Clinical Site #4, Indianapolis
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 1 Okt 2026 · NCT05176483Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment
- UChicago Medicine Northwest Indiana, Crown Point
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 1 Okt 2026 · NCT06589804Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery
- IU Health North Hospital, Carmel
- UChicago Medicine Northwest Indiana, Crown Point
- Indiana University/Melvin and Bren Simon Cancer Center, Indianapolis
- dan 3 lainnya
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 14 Sep 2026 · NCT02734537A Study of IDP-001 in Advanced or Metastatic Solid Tumors
- Community Cancer Center North, Indianapolis
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 3 Sep 2026 · NCT07602842Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer
- Baptist Health Floyd, New Albany
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 17 Agu 2026 · NCT06532279ctHPVDNA in HPV Positive Squamous Cell Carcinoma of the Oropharynx
- IU Health Joe and Shelly Schwarz Cancer Center, Carmel
- Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis
Menerima peserta
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 11 Agu 2026 · NCT06915038A Phase 1 of CTX-8371 in Patients With Advanced Malignancies
- Fort Wayne Medical Oncology and Hematology, Fort Wayne
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 28 Jul 2026 · NCT06150664A Study of Sigvotatug Vedotin in Advanced Solid Tumors
- UChicago Medicine - Northwest Indiana, Crown Point
- Fort Wayne Medical Oncology and Hematology, Inc, Fort Wayne
- Community Health Network, Inc, Indianapolis
- dan 3 lainnya
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 6 Jul 2026 · NCT04389632Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan
- Fort Wayne Medical Oncology and Hematology, Inc /ID# 232593, Fort Wayne
- Community Health Network, Inc. /ID# 243011, Indianapolis
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 23 Jun 2026 · NCT05005403A Study of Dostarlimab vs Placebo After Chemoradiation in Adult Participants With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma
- GSK Investigational Site, Fort Wayne
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 26 Mei 2026 · NCT06256588A Study of VET3-TGI in Patients With Solid Tumors
- Community Health Network, Indianapolis
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 7 Apr 2026 · NCT06444815A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer
- Community Health Network, Indianapolis
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 4 Nov 2025 · NCT05902988Dari ClinicalTrials.gov, data diambil 5 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.